Thus, based on the available clinical evidence, the American Diabetes Association (ADA) [100] recommended GLP-1 RAs with demonstrated cardiovascular disease benefit as part of a comprehensive cardiorenal risk-reduction strategy for patients with T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.